...
首页> 外文期刊>Tumori. >Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer.
【24h】

Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer.

机译:上皮性卵巢癌患者对术后化疗进行病理完全反应后复发的相关因素。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS AND BACKGROUND: It has been appreciated for some time that the lack of detection of ovarian cancer at clinical and pathological (second-look laparotomy) evaluation is not synonymous with cure. The goal of this study was to define clinical risk factors for recurrence after complete pathological response to postoperative chemotherapy in patients with epithelial ovarian cancer. METHODS: Fifty-seven patients who met the inclusion criteria of our study were evaluated. The characteristics (age, menopausal status, histological subtype, tumor grade, presence of ascites at diagnosis, type of omentectomy, FIGO stage, and residual tumor volume after primary surgery) of patients with and those without tumor recurrence were compared. RESULTS: The median follow-up was 52 months (range, 15-142 months). The overall survival rates of the patients were 100%, 96%, and 87% at 1, 3 and 5 years, respectively. At the time of the study analysis, 21 of 57 (37%) patients had recurrent disease. The median time to recurrence was 16 months. Recurrences were most frequent in the pelvis and abdominal cavity (38%). Age, menopausal status, stage at diagnosis, and residual tumor volume after initial surgery were significantly related to the risk of recurrence in univariate analysis (P = 0.039, 0.038, 0.004, and 0.000, respectively). Residual tumor volume after initial surgery was found to be the only significant independent prognostic factor (P = 0.049, HR: 0.16, 95% CI: 0.02-0.99). CONCLUSION: We believe it is necessary to conduct randomized studies on this issue because insight into predictors of recurrence after pathological complete response to postoperative chemotherapy could be used to select patients for trials of consolidation therapy.
机译:目的和背景:人们已经认识到一段时间以来,在临床和病理(二次剖腹探查术)评估中缺乏检测卵巢癌并不是治愈的同义词。这项研究的目的是确定上皮性卵巢癌患者对术后化疗的完全病理反应后复发的临床危险因素。方法:对符合本研究纳入标准的57例患者进行了评估。比较了有和无肿瘤复发患者的特征(年龄,更年期状态,组织学亚型,肿瘤等级,诊断时有腹水,网膜切除术类型,FIGO分期和初次手术后肿瘤残留量)。结果:中位随访时间为52个月(范围15-142个月)。在1、3和5年时,患者的总生存率分别为100%,96%和87%。在进行研究分析时,57例患者中有21例(37%)患有复发性疾病。复发的中位时间为16个月。骨盆和腹腔复发最频繁(38%)。在单因素分析中,年龄,绝经状态,诊断分期和术后残余肿瘤体积与复发风险显着相关(分别为P = 0.039、0.038、0.004和0.000)。发现初始手术后的残余肿瘤体积是唯一重要的独立预后因素(P = 0.049,HR:0.16,95%CI:0.02-0.99)。结论:我们认为有必要对该问题进行随机研究,因为对术后化疗病理完全缓解后复发预测因素的洞察力可用于选择巩固治疗试验的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号